Literature DB >> 7429305

Increased C1q binding and arthritis in primary biliary cirrhosis.

J P Crowe, M G Molloy, I Wells, B R Thompson, E J Holborow, E Hamilton, R Williams.   

Abstract

Using the C1q binding assay, circulating immune complexes were detected in 31 of 50 (62%) patients with primary biliary cirrhosis and 17 of these had arthritis. This took the form of a seropositive inflammatory polyarthritis in 12 of 18 patients with C1q binding greater than or equal to 20%, whereas a milder seronegative arthritis associated with scleroderma and Raynaud's phenomenon was found in five of 13 patients with C1q binding < 20%. Only two of the 19 patients with normal binding had arthritis and this was of a mild and transient nature. There was a positive correlation between C1q binding and the serum concentrations of IgG and IgM. Results also supported the hypothesis that circulating immune complexes may be involved in the development of arthritis in patients with primary biliary cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7429305      PMCID: PMC1419072          DOI: 10.1136/gut.21.5.418

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  17 in total

1.  Systemic scleroderma, A clinical study of 727 cases.

Authors:  D L TUFFANELLI; R K WINKELMANN
Journal:  Arch Dermatol       Date:  1961-09

2.  Pathogenesis of serum sickness.

Authors:  F J DIXON; J J VAZQUEZ; W O WEIGLE; C G COCHRANE
Journal:  AMA Arch Pathol       Date:  1958-01

3.  Arthritis and primary biliary cirrhosis.

Authors:  D L Child; J A Mathews; R P Thompson
Journal:  Br Med J       Date:  1977-08-27

Review 4.  Nonsuppurative destructive chronic cholangitis and chronic hepatitis.

Authors:  H Popper; F Schaffner
Journal:  Prog Liver Dis       Date:  1970

5.  Antibodies to cytoplasmic antigens in primary biliary cirrhosis and chronic active hepatitis.

Authors:  F Paronetto; F Schaffner; H Popper
Journal:  J Lab Clin Med       Date:  1967-06

6.  Rheumatic disorders in primary biliary cirrhosis.

Authors:  A K Clarke; R M Galbraith; E B Hamilton; R Williams
Journal:  Ann Rheum Dis       Date:  1978-02       Impact factor: 19.103

7.  Immune complexes in acute and chronic liver disease.

Authors:  H C Thomas; D De Villiers; B Potter; H Hodgson; S Jain; D P Jewell; S Sherlock
Journal:  Clin Exp Immunol       Date:  1978-02       Impact factor: 4.330

8.  Circulating conversion products of C3 in liver disease. Evidence for in vivo activation of the complement system.

Authors:  P Teisberg; E Gjone
Journal:  Clin Exp Immunol       Date:  1973-08       Impact factor: 4.330

9.  The pathogenesis of arthritis associated with acute hepatitis-B surface antigen-positive hepatitis. Complement activation and characterization of circulating immune complexes.

Authors:  J R Wands; E Mann; E Alpert; K J Isselbacher
Journal:  J Clin Invest       Date:  1975-05       Impact factor: 14.808

10.  Detection of immune complexes in unheated sera by modified 125I-Clq binding test. Effect of heating on the binding of Clq by immune complexes and application of the test to systemic lupus erythematosus.

Authors:  R H Zubler; G Lange; P H Lambert; P A Miescher
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

View more
  4 in total

Review 1.  Primary biliary cirrhosis.

Authors:  J Neuberger; M Lombard; R Galbraith
Journal:  Gut       Date:  1991-09       Impact factor: 23.059

Review 2.  Clinical associations between arthritis and liver disease.

Authors:  P R Mills; R D Sturrock
Journal:  Ann Rheum Dis       Date:  1982-06       Impact factor: 19.103

3.  Endothelial cell damage in primary biliary cirrhosis: influence of cholestasis and immunological mechanisms.

Authors:  A D Blann; C Babbs; J M Neuberger
Journal:  Clin Exp Immunol       Date:  1992-10       Impact factor: 4.330

4.  Circulating immune complexes in primary biliary cirrhosis: interactions with lymphoid cells.

Authors:  J L Dienstag; A M Savarese; R B Cohen; A K Bhan
Journal:  Clin Exp Immunol       Date:  1982-10       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.